The Singapore Translational Cancer Consortium (STCC) was established in 2020 as a nationally coordinated initiative and network to synergize cancer research and translational capabilities across Singapore.
The STCC joint platform enables collaboration between basic, clinical and translational researchers to explore novel approaches, push promising lines of research and translation, and seed ideas for larger competitive translational grants.
We partner with key stakeholders and institutions to implement joint platforms that are functionally integrated and operational in support of the nation’s long term goals to achieve value-based healthcare and economic outcomes through deeper industry collaborations, patents and invention disclosures, start-ups and clinically validated diagnostics.